Last reviewed · How we verify
Placebo+JYB1904
JYB1904 is an investigational therapeutic being evaluated in combination with placebo control in a Phase 3 trial, though its specific molecular mechanism is not publicly disclosed.
At a glance
| Generic name | Placebo+JYB1904 |
|---|---|
| Also known as | Placebo+JYB1904 Injection |
| Sponsor | Jemincare |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a Phase 3 candidate from Jemincare, JYB1904 is undergoing late-stage clinical evaluation; however, detailed mechanistic information regarding its molecular target, drug class, and mode of action is not available in public databases. The placebo-controlled design is standard for efficacy and safety assessment at this stage.
Approved indications
Common side effects
Key clinical trials
- Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis (PHASE2)
- Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy (PHASE2)
- Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. (PHASE3)
- Trial of JYB1904 in Chronic Spontaneous Urticaria. (PHASE2)
- Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |